Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $122.42K, compared with -$149.11K a year earlier. Trailing-twelve-month accounts payables was -$109.49K. Over 3 fiscal years it compounded at +121.5% a year.
Context
- Accounts payables amounted to 28.0% of revenue in FY2025.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near $122.42K or moves back toward the trailing-twelve-month quarterly average of -$27.37K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (381.01K) USD
- Year-over-year change
- -154.1%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (381.01K) | -154.1% |
| FY2024 | 2024-12-31 | (149.94K) | -111.4% |
| FY2023 | 2023-12-31 | 1.32M | +3865.7% |
| FY2022 | 2022-12-31 | (35.07K) | +97.8% |
| FY2021 | 2021-12-31 | (1.58M) | — |
Accounts Payables vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 accounts payables of $109.49K is the 7th largest of the 9 companies compared; the peer median is $236.88K.
- Its year-over-year change of -55.4% is the 6th highest of 9, against a peer median of +18.6%.
- Accounts payables amounts to 7.7% of revenue for COEP, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $12.2M | +1170.0% | +236.9% | — |
| LTM Mar 2026 | $4.9M | +28.5% | +8.8% | 1472.1% | |
| LTM Mar 2026 | $1.88M | -646.1% | — | — | |
| LTM Mar 2026 | $1.59M | +8.7% | — | 1.1% | |
| LTM Mar 2026 | $458K | +239.3% | +138.4% | 1.4% | |
| LTM Mar 2026 | $424K | -76.4% | — | — | |
| LTM Mar 2026 | $109.49K | -55.4% | +121.5% | 7.7% | |
| LTM Mar 2026 | $64K | +100.9% | — | 2.8% | |
| LTM Mar 2026 | $49.76K | -145.7% | — | — | |
| Peer median (excluding COEP) | $236.88K | +18.6% | +138.4% | 2.1% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (11.92M) |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| Deferred Income Tax | 5.34M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 0 | 477.5K | 1.1M | 1.22M |
| Change in Working Capital | (2.98M) | (550.34K) | 1.73M | (125.26K) | (1.46M) |
| Accounts Receivables | 21.79K | (8.08K) | (30.9K) | (234.74K) | (7.35K) |
| Inventory | (422.02K) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | (35.07K) | 1.32M | (149.94K) | (381.01K) |
| Other Working Capital | (1M) | (507.19K) | 437.31K | 259.42K | (1.07M) |
| Other Non-Cash Items | 4.26M | 33.25M | 10.79M | 2.21M | 2.34M |
| Operating Cash Flow | (4.49M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
| Capital Expenditures | (1.75M) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.75M) | 0 | 0 | 0 | 0 |
| Debt Repayment | (1.62M) | (2.42M) | (575K) | 1.2M | 771.25K |
| Common Stock Issued | 10.14M | 3.27M | 5.29M | 100K | 12.97M |
| Common Stock Repurchased | (247.17K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50.9K) | 4.63M | 200K | 500K | 0 |
| Financing Cash Flow | 8.22M | 5.49M | 4.92M | 5.71M | 13.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.98M | 1.61M | (2.32M) | (936.25K) | 5.14M |
| Free Cash Flow | (6.24M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.